Derik De Bruin
Stock Analyst at B of A Securities
(4.97)
# 19
Out of 4,873 analysts
211
Total ratings
65.73%
Success rate
89.33%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $117.64 | +8.81% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $5.05 | +117.82% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $51.17 | +27.03% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $7.23 | +121.30% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $346.80 | +18.22% | 13 | Feb 13, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $96.39 | +43.17% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $404.37 | +63.22% | 18 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $158.58 | +48.19% | 3 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $148.40 | +41.51% | 5 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $222.68 | +59.42% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $24.59 | +5.73% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $262.53 | +3.23% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $179.90 | +1.17% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $39.66 | +101.71% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $197.47 | +46.86% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $24.77 | -39.44% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $5.31 | +295.48% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $10.89 | +129.57% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $20.60 | +55.34% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $91.52 | +9.27% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $64.83 | +32.65% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.08 | +219.02% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,185.18 | +28.67% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.97 | +229.95% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $148.54 | +75.04% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.19 | +1,205.77% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $47.23 | +32.52% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $157.77 | -23.94% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.44 | +525.00% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $530.50 | -55.70% | 3 | Nov 2, 2018 |
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $117.64
Upside: +8.81%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $5.05
Upside: +117.82%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $51.17
Upside: +27.03%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $7.23
Upside: +121.30%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $346.80
Upside: +18.22%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $96.39
Upside: +43.17%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $404.37
Upside: +63.22%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $158.58
Upside: +48.19%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $148.40
Upside: +41.51%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $222.68
Upside: +59.42%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $24.59
Upside: +5.73%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $262.53
Upside: +3.23%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $179.90
Upside: +1.17%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $39.66
Upside: +101.71%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $197.47
Upside: +46.86%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $24.77
Upside: -39.44%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $5.31
Upside: +295.48%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $10.89
Upside: +129.57%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $20.60
Upside: +55.34%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $91.52
Upside: +9.27%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $64.83
Upside: +32.65%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.08
Upside: +219.02%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,185.18
Upside: +28.67%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.97
Upside: +229.95%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $148.54
Upside: +75.04%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.19
Upside: +1,205.77%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $47.23
Upside: +32.52%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $157.77
Upside: -23.94%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.44
Upside: +525.00%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $530.50
Upside: -55.70%